Drugs / LCAR-BCX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04601935 | Oct 2020 → Jan 2023 | refractory plasma cell neoplasm | Weijun Fu | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LCAR-BCX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04601935 ↗ |
| Modality | Cell therapy | “LCAR-BCX cell therapy” NCT04601935 ↗ |